Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Initiative Will Produce Biosimilars Of Lantus, Humalog And Novolog
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
